\n<\/p>\n
WASHINGTON — <\/span>President Donald Trump is set to announce Friday that all 50 states will join in on a program set to provide most favored nation pricing<\/a> to some drugs within the Medicaid program, bringing the net price of selected drugs down to prices paid in certain other countries.<\/p>\n The Trump administration claims that Medicaid will save billions on prescription drug costs as a result of the plan, dubbed the Medicaid \u201cGENEROUS\u201d model. Experts say the savings are unclear since the content of the deals isn’t public.<\/p>\n Friday’s announcement comes as cost-of-living issues are at the forefront<\/a> of voters\u2019 concerns ahead of the midterm elections in November. In a way to address affordability concerns, Trump has cut deals with pharmaceutical companies so that the cost of some drugs in the U.S. would not be dramatically higher than in other affluent nations. <\/p>\n Last year, Trump signed an executive order instituting a \u201cMost Favored Nations\u201d policy, where the U.S. would commit to paying the same price for medications as the nation that pays the lowest price anywhere in the world. <\/p>\n The White House in May estimated<\/a> that Trump\u2019s deals with pharmaceutical companies<\/a> to lower some of their U.S. prescription drug prices to levels charged in other countries could save $529 billion over the next 10 years.<\/p>\n Patients in Medicaid, the state- and federally-funded program for people with low incomes, already pay a nominal co-payment of a few dollars to fill their prescriptions, but lower prices could help state budgets that fund the programs.<\/p>\n The true cost of the claimed savings is unclear since few details of the deals struck by the Trump administration and participating pharmaceutical companies have been made public, making it hard to independently verify the projected savings.<\/p>\n Kathy Hempstead, a senior policy advisor at the Robert Wood Johnson Foundation, told The Associated Press that there is significant pressure on the administration to provide more granular data to justify its cost-savings claims, and that the lack of information creates a barrier to legislative action.<\/p>\n \u201cHe is saying Congress should codify all of his MFN arrangements,” Hempstead said. \u201cBut it\u2019s kind of unreasonable because it\u2019s not clear what Congress would actually do. No one knows what is in these deals.\u201d<\/p>\n She added that there is concern about whether the current administration\u2019s tenure will affect the longevity of these price cuts and whether prices will revert once the administration leaves.<\/p>\n Some want to see more people benefit from lower drug pricing. <\/p>\n JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, said in a statement that Friday’s announcement reflects \u201cmeaningful progress, but that progress remains incomplete,” as millions of Americans not enrolled in government healthcare want lower drug prices.<\/p>\n Drug prices for patients in the U.S. can depend on a number of factors, including the competition a treatment faces and insurance coverage. Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost.<\/p>\n<\/div>\n